• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

依维莫司洗脱生物可吸收血管支架吸收后的边缘血管反应——一项为期5年的光学相干断层扫描系列研究

Edge Vascular Response After Resorption of the Everolimus-Eluting Bioresorbable Vascular Scaffold - A 5-Year Serial Optical Coherence Tomography Study.

作者信息

Tateishi Hiroki, Suwannasom Pannipa, Sotomi Yohei, Nakatani Shimpei, Ishibashi Yuki, Tenekecioglu Erhan, Abdelghani Mohammad, Cavalcante Rafael, Zeng Yaping, Grundeken Maik J, Albuquerque Felipe N, Veldhof Susan, Onuma Yoshinobu, Serruys Patrick W

机构信息

Thoraxcenter, Erasmus Medical Center.

出版信息

Circ J. 2016 Apr 25;80(5):1131-41. doi: 10.1253/circj.CJ-15-1325. Epub 2016 Mar 3.

DOI:10.1253/circj.CJ-15-1325
PMID:26936236
Abstract

BACKGROUND

The edge vascular response (EVR) has been linked to important prognostic implications in patients treated with permanent metallic stents. We aimed to investigate the relationship of EVR with the geometric changes in the everolimus-eluting bioresorbable scaffold using serial optical coherence tomography (OCT) analysis.

METHODS AND RESULTS

In the first-in-man ABSORB trial, 28 patients (29 lesions) underwent serial OCT at 4 different time points (Cohort B1: post-procedure, 6, 24, and 60 months [n=13]; Cohort B2: post-procedure, 12, 36, and 60 months [n=15]) following implantation of the scaffold. In Cohort B1, there was no significant luminal change at the distal or proximal edge segment throughout the entire follow-up. In contrast, there was a significant reduction of the lumen flow area (LFA) of the scaffold between post-procedure and 6 months (-1.03±0.49 mm(2)[P<0.001]), whereas between 6 and 60 months the LFA remained stable (+0.31±1.00 mm(2)[P=0.293]). In Cohort B2, there was a significant luminal reduction of the proximal edge between post-procedure and 12 months (-0.57±0.74 mm(2)[P=0.017]), whereas the lumen area remained stable (-0.26±1.22 mm(2)[P=0.462]) between 12 and 60 months. The scaffold LFA showed a change similar to that observed in Cohort B1.

CONCLUSIONS

Our study demonstrated a reduction in the scaffold luminal area in the absence of major EVR, suggesting that the physiological continuity of the lumen contour is restored long term. (Circ J 2016; 80: 1131-1141).

摘要

背景

边缘血管反应(EVR)与接受永久性金属支架治疗的患者的重要预后影响相关。我们旨在通过连续光学相干断层扫描(OCT)分析研究EVR与依维莫司洗脱生物可吸收支架几何变化之间的关系。

方法与结果

在首例人体ABSORB试验中,28例患者(29处病变)在植入支架后的4个不同时间点接受了连续OCT检查(B1组:术后、6个月、24个月和60个月[n = 13];B2组:术后、12个月、36个月和60个月[n = 15])。在B1组中,整个随访期间远端或近端边缘节段的管腔没有明显变化。相比之下,术后至6个月期间支架的管腔血流面积(LFA)显著减少(-1.03±0.49 mm²[P < 0.001]),而6至60个月期间LFA保持稳定(+0.31±1.00 mm²[P = 0.293])。在B2组中,术后至12个月期间近端边缘的管腔显著减小(-0.57±0.74 mm²[P = 0.017]),而12至60个月期间管腔面积保持稳定(-0.26±1.22 mm²[P = 0.462])。支架LFA的变化与B1组观察到的相似。

结论

我们的研究表明,在没有明显EVR的情况下,支架管腔面积减小,这表明管腔轮廓的生理连续性长期得以恢复。(《循环杂志》2016年;80:1131 - 1141)

相似文献

1
Edge Vascular Response After Resorption of the Everolimus-Eluting Bioresorbable Vascular Scaffold - A 5-Year Serial Optical Coherence Tomography Study.依维莫司洗脱生物可吸收血管支架吸收后的边缘血管反应——一项为期5年的光学相干断层扫描系列研究
Circ J. 2016 Apr 25;80(5):1131-41. doi: 10.1253/circj.CJ-15-1325. Epub 2016 Mar 3.
2
Scaffold and edge vascular response following implantation of everolimus-eluting bioresorbable vascular scaffold: a 3-year serial optical coherence tomography study.载有依维莫司的可吸收血管支架植入后支架及边缘血管的反应:一项 3 年的光学相干断层扫描系列研究。
JACC Cardiovasc Interv. 2014 Dec;7(12):1361-9. doi: 10.1016/j.jcin.2014.06.025. Epub 2014 Nov 12.
3
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials.Absorb 依维莫司洗脱生物可吸收血管支架和 XIENCE V 金属依维莫司洗脱支架植入后的边缘血管反应。首次在 6 个月和 2 年时的系列随访评估:来自首例人体 ABSORB 队列 B 和 SPIRIT II 试验的见解。
EuroIntervention. 2013 Oct;9(6):709-20. doi: 10.4244/EIJV9I6A115.
4
A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.载有依维莫司的聚乳酸可吸收生物支架治疗冠状动脉狭窄:5 年随访。
J Am Coll Cardiol. 2016 Feb 23;67(7):766-76. doi: 10.1016/j.jacc.2015.11.060.
5
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.第二代生物可吸收依维莫司药物洗脱血管支架治疗冠状动脉原发狭窄的临床和影像学 6 个月随访结果。
Circulation. 2010 Nov 30;122(22):2301-12. doi: 10.1161/CIRCULATIONAHA.110.970772. Epub 2010 Nov 15.
6
Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).植入可吸收依维莫司洗脱完全生物可吸收血管支架后急性支架断裂和晚期结构不连续性的发生率和影像学结果:ABSORB 队列 B 试验的光学相干断层成像评估(生物可吸收依维莫司洗脱冠状动脉支架系统治疗初发原生冠状动脉病变患者的临床评价)。
JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11. doi: 10.1016/j.jcin.2014.06.016.
7
Change in lumen eccentricity and asymmetry after treatment with Absorb bioresorbable vascular scaffolds in the ABSORB cohort B trial: a five-year serial optical coherence tomography imaging study.在 ABSORB 队列 B 试验中使用 Absorb 生物可吸收血管支架治疗后管腔偏心度和不对称性的变化:一项为期五年的光学相干断层扫描成像研究。
EuroIntervention. 2017 Apr 7;12(18):e2244-e2252. doi: 10.4244/EIJ-D-16-00740.
8
First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.第二代可吸收依维莫司洗脱生物可吸收血管支架的 6 个月和 2 年的首次系列评估:多模态影像学研究。
Circ Cardiovasc Interv. 2012 Oct;5(5):620-32. doi: 10.1161/CIRCINTERVENTIONS.112.971549. Epub 2012 Oct 9.
9
Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.依维莫司洗脱可吸收生物可降解血管支架植入后血管壁变化的动态研究:一项在6个月、12个月、24个月和36个月时进行的多成像模态研究
EuroIntervention. 2014 Mar 20;9(11):1271-84. doi: 10.4244/EIJV9I11A217.
10
Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.经全吸收聚合物雷帕霉素洗脱支架冠状动脉植入治疗初发冠状动脉疾病患者的 5 年临床和功能多层螺旋 CT 血管造影结果:ABSORB 队列 A 试验。
JACC Cardiovasc Interv. 2013 Oct;6(10):999-1009. doi: 10.1016/j.jcin.2013.05.017.

引用本文的文献

1
First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIODAPTOR-RCT.第一项比较西罗莫司洗脱生物适配器与佐他莫司洗脱药物洗脱支架治疗冠状动脉病变患者的随机对照试验:来自多中心、国际BIODAPTOR-RCT的12个月临床和影像学数据。
EClinicalMedicine. 2023 Oct 24;65:102304. doi: 10.1016/j.eclinm.2023.102304. eCollection 2023 Nov.
2
Advances in the development of biodegradable coronary stents: A translational perspective.可生物降解冠状动脉支架的发展进展:转化医学视角
Mater Today Bio. 2022 Jul 19;16:100368. doi: 10.1016/j.mtbio.2022.100368. eCollection 2022 Dec.
3
Successful bailout stenting strategy against rare spontaneous retrograde dissection of partially absorbed magnesium-based resorbable scaffold: A case report.针对部分吸收的镁基可吸收支架罕见自发性逆行夹层的成功补救支架置入策略:一例报告。
World J Clin Cases. 2021 Feb 16;9(5):1148-1155. doi: 10.12998/wjcc.v9.i5.1148.
4
Bioresorbable vascular scaffolds - basic concepts and clinical outcome.生物可吸收血管支架——基本概念和临床结果。
Nat Rev Cardiol. 2016 Dec;13(12):719-729. doi: 10.1038/nrcardio.2016.151. Epub 2016 Sep 29.